A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.

CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate